Endocrine Abstracts

Metformin has recently emerged as a potential therapeutic tool for different tumour pathologies, including prostate cancer (PCa)1, one of the leading causes of cancer-deaths in men worldwide. However, the molecular mechanisms underlying the antitumor effects of metformin in PCa are not fully elucidated. In this context, previous reports have suggested a relationship between metformin and the process of alternative splicing in some cell-types. Nevertheless, the poten...

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETscan be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resectionis the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are pr...

Craniopharyngiomas are rare benign epithelial tumors derived from remains of Rathke’s pouch. They are more prevalent in childhood, adolescence, and adults <50 years, and, commonly, are usually diagnosed after being associated with serious comorbidities when the development of the tumor is already advanced. To date, first-line therapy is usually surgery, but frequently the resection is not complete, causing high rates of recurrence. Therefore, the identification of ne...

Obesity is a chronic metabolic disease associated with important metabolic and inflammatory comorbidities, which can be reversed or improved after bariatric-surgery (BS). However, some underlying mechanisms, independent of weight-loss, are still unknown. In this context, dysregulations in the inflammasome, a multiproteic complex that promotes cytokine maturation and induces cellular pyroptosis, has been associated to the development/stage of some cancer-types and obesity. Howe...

Gliomas are a common tumor type that affects the glial cells with common features of malignant tumors such as aggressive invasiveness, malignant transformation and vascular proliferation through the central nervous system. Currently, standard therapeutic strategies to treat malignant gliomas are not efficient having alow-rate survival (~12 months). Hence, there is a clear necessity for the identification of novel diagnostic/prognostic tools and therapeutic strategies to m...

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH). Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are preferre...

Somatostatin (SST), Cortistatin (CORT), Neuronostatin (NST) and their receptors [SST/CORT-receptors (sst1–5/sst5TMD4-TMD5) and NST-receptor (GPR107)] comprise a hormonal pleiotropic system involved in the regulation of multiple pathophysiological functions. Certain components of this system are dysregulated in endocrine-related cancers, including prostate cancer (PCa), wherein we have found that alterations in specific components of this regulatory system [i.e. NST-GPR10...

Development and progression of liver diseases, from non-alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH), and hepatocellular carcinoma (HCC), seem to be accompanied by a dysregulation of the expression of alternative splicing variants (SVs) and appearance of aberrant SVs. The splicing factor 3B subunit 1 (SF3B1) represents a crucial player for the functional assembly of the spliceosome, the core machinery that controls the splicing process, and its activity can ...

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...